Oncocyte extends outside date for Razor Genomics sale to Feb 15, 2023

Insight Molecular Diagnostics Inc.

First Amendment extends closing deadline from Feb 1 to Feb 15, 2023 for sale of 70% of Razor Genomics to Dragon Scientific.
Oncocyte will retain 30% equity interest in Razor after closing.
No other terms of the original Stock Purchase Agreement were amended.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Insight Molecular Diagnostics Inc. amended First Amendment to Stock Purchase Agreement with Dragon Scientific, LLC valued at Extended the Outside Date from February 1, 2023 to February 15, 2023 (effective 2023-01-30).

Action: amendment
Agreement: equity purchase
Counterparty: Dragon Scientific, LLC
Value: Extended the Outside Date from February 1, 2023 to February 15, 2023
Effective: 2023-01-30

Exact text from the filing

On January 30, 2023, the Company, Buyer and Razor entered into a First Amendment to Stock Purchase Agreement whereby the parties agreed to the extend the Outside Date, as set forth in Section 3.1(e) of the Agreement, to February 15, 2023 (“First Amendment”). No other provisions of the Agreement were otherwise amended or waived by the First Amendment, and the Agreement remains in full force and effect.

View on SEC.gov

Browse all material agreements →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-003528

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.